Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
146.00    -6.80 (-4.45%)
Bid:
146.00
Ask:
153.40
Spread: 7.40 (5.068%)
Market Cap: £874.50m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

Trading Statement

24 Jun 2015 07:00

RNS Number : 0217R
Elementis PLC
24 June 2015
 



Elementis plc - Trading update

 

Elementis plc (ELM.L, the "Company" or the "Group"), the Global Specialty Chemicals Company, today issues a trading update ahead of its interim results for the half year ending 30 June 2015, which will be announced on 28 July 2015.

 

Specialty Products continues to make solid progress in terms of leveraging its strong market positions and geographic diversity, and developing new and innovative products to solve our customers' formulary challenges. Market share and contribution margins have remained stable and trading in the first half of the year is anticipated to be in line with management's expectations in most of our key markets. However, temporary market dynamics experienced in the second quarter of the year will most likely negatively influence our full year result.

 

· As recent commentary from the oil sector confirms, there has been a further significant reduction in oil projects in North America and therefore drilling activity has been further curtailed. As a result, we now expect our sales of additives for the first half and the year as a whole to the oilfield drilling market to be at least 30 per cent lower than the previous year, driven by lower volumes.

 

· In coatings additives, the Group continues to make good progress in North America, where the uptake of the new additives line for decorative coatings from our New Martinsville facility is continuing to gain traction with customers. Sales to Latin America have also been robust, based on synergy projects from the previously acquired Watercryl business. In Europe, where underlying economic activity still remains subdued, Group sales for the first half of the year, on a constant currency basis, are expected to be ahead of the same period last year. However, additives sales in China have experienced a reduction in demand during the second quarter of the year and, while the Group still expects sales to be ahead of prior year for the year as a whole, Asia Pacific sales in the first half will be similar to the same period last year. Consequently, overall sales of coatings additives for the first six months of the year, on a constant currency basis, are expected to be at a similar level to the same period last year.

 

· In personal care, the business continues to expand through new product sales and investments into new geographies. However, sales in Latin America have been impacted by significant local currency weakness. This has resulted in the business opting to cease supplying to a number of applications where returns have fallen below an acceptable threshold. The business is taking decisive action to address this competitive dynamic and market share gains from new product introductions have helped to offset the Latin America shortfall. Therefore, sales for the first half will be similar to the strong 2014 first half results. Additionally, positive trends in other markets and geographies mean that full year sales, on a constant currency basis, are expected to be ahead of the previous year.

 

In Chromium, the market trends outlined in the Group's Interim Management Statement in April have continued through the balance of the first half of the year. As such, management expects the operating profit for the full year to be in line with the stated strategy for the business of "stable earnings and cash flow" and the first half result to be similar to the same period last year.

 

The Group's balance sheet remains in a strong position and is expected to show a net cash position at the end of the current year. While the Group remains confident in continuing to make progress in the medium term, the cumulative impact of short term issues arising during the second quarter, as described above, is that earnings per share for the full year are anticipated to be below the current range of market expectations.

 

 

ENDS

 

Enquiries:

Elementis + 44 (0) 207 408 9300

David Dutro, Chief Executive

Brian Taylorson, Finance Director

  

FTI Consulting

 

 

+ 44 (0) 203 727 1000

Deborah Scott

Matthew Cole

  

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFJMPTMBATBIA
Date   Source Headline
1st Sep 20239:42 amRNSTotal Voting Rights
1st Aug 20239:44 amRNSTotal Voting Rights
27th Jul 20232:16 pmRNSHolding(s) in Company
27th Jul 20237:00 amRNSHalf-year Report
20th Jul 202312:58 pmRNSHolding(s) in Company
3rd Jul 202310:21 amRNSTotal Voting Rights
29th Jun 20234:29 pmRNSDirector/PDMR Shareholding
23rd Jun 20239:32 amRNSDirector/PDMR Shareholding
30th May 20238:06 amRNSDirector Declaration
2nd May 20239:37 amRNSTotal Voting Rights
26th Apr 20232:12 pmRNSResult of AGM
26th Apr 20237:00 amRNSAGM Trading Statement
17th Apr 202310:15 amRNSDirector/PDMR Shareholding
17th Apr 202310:10 amRNSDirector/PDMR Shareholding
13th Apr 20234:24 pmRNSDirector/PDMR Shareholding
3rd Apr 202311:28 amRNSDirector Declaration
3rd Apr 20239:34 amRNSTotal Voting Rights
24th Mar 20239:27 amRNSDirector/PDMR Shareholding
22nd Mar 20234:02 pmRNSAnnual Financial Report & Notice of AGM
17th Mar 20232:58 pmRNSAdditional Listing
14th Mar 20237:30 amRNSDirector Declaration
9th Mar 20232:50 pmRNSDirector/PDMR Shareholding
9th Mar 20232:47 pmRNSDirector/PDMR Shareholding
7th Mar 20237:00 amRNSPreliminary results year ended 31 December 2022
1st Mar 20239:53 amRNSBlock listing Interim Review
1st Mar 20239:39 amRNSTotal Voting Rights
31st Jan 20233:04 pmRNSSale of Chromium business
19th Jan 20237:00 amRNSTrading Update
3rd Jan 20239:47 amRNSTotal Voting Rights
8th Dec 20222:10 pmRNSDirector/PDMR Shareholding
30th Nov 20227:00 amRNSSale of Chromium business
23rd Nov 20223:54 pmRNSHolding(s) in Company
16th Nov 20221:43 pmRNSHolding(s) in Company
10th Nov 20229:40 amRNSHolding(s) in Company
10th Nov 20227:00 amRNSDirectorate Change
1st Nov 20229:48 amRNSTotal Voting Rights
31st Oct 20223:23 pmRNSHolding(s) in Company
26th Oct 20227:00 amRNSQ3 Trading Update
18th Oct 20223:13 pmRNSHolding(s) in Company
3rd Oct 20229:39 amRNSTotal Voting Rights
29th Sep 202212:45 pmRNSDirector/PDMR Shareholding
29th Sep 202210:12 amRNSDirector/PDMR Shareholding
22nd Sep 202211:17 amRNSDirector/PDMR Shareholding
21st Sep 20224:58 pmRNSDirector/PDMR Shareholding
21st Sep 20223:48 pmRNSDirector/PDMR Shareholding
6th Sep 202212:52 pmRNSDirector Declaration
5th Sep 20224:14 pmRNSAdditional Listing
1st Sep 202212:39 pmRNSHolding(s) in Company
1st Sep 20229:15 amRNSBlock listing Interim Review
1st Sep 20229:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.